Literature DB >> 32747359

Nucleocapsid Protein Precursors NCp9 and NCp15 Suppress ATP-Mediated Rescue of AZT-Terminated Primers by HIV-1 Reverse Transcriptase.

Moisés A Árquez1,2, Samara Martín-Alonso3, Robert J Gorelick4, Walter A Scott5, Antonio J Acosta-Hoyos6, Luis Menéndez-Arias7.   

Abstract

In HIV-1, development of resistance to AZT (3'-azido-3'-deoxythymidine) is mediated by the acquisition of thymidine analogue resistance mutations (TAMs) (i.e., M41L, D67N, K70R, L210W, T215F/Y, and K219E/Q) in the viral reverse transcriptase (RT). Clinically relevant combinations of TAMs, such as M41L/T215Y or D67N/K70R/T215F/K219Q, enhance the ATP-mediated excision of AZT monophosphate (AZTMP) from the 3' end of the primer, allowing DNA synthesis to continue. Additionally, during HIV-1 maturation, the Gag polyprotein is cleaved to release a mature nucleocapsid protein (NCp7) and two intermediate precursors (NCp9 and NCp15). NC proteins interact with the viral genome and facilitate the reverse transcription process. Using wild-type and TAM-containing RTs, we showed that both NCp9 and NCp15 inhibited ATP-mediated rescue of AZTMP-terminated primers annealed to RNA templates but not DNA templates, while NCp7 had no effect on rescue activity. RNase H inactivation by introducing the active-site mutation E478Q led to the loss of the inhibitory effect shown by NCp9. NCp15 had a stimulatory effect on the RT's RNase H activity not observed with NCp7 and NCp9. However, analysis of RNase H cleavage patterns revealed that in the presence of NCp9, RNA/DNA complexes containing duplexes of 12 bp had reduced stability in comparison with those obtained in the absence of NC or with NCp7 or NCp15. These effects are expected to have a strong influence on the inhibitory action of NCp9 and NCp15 by affecting the efficiency of RNA-dependent DNA polymerization after unblocking DNA primers terminated with AZTMP and other nucleotide analogues.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  AZT; HIV; NC protein; RNase H; drug resistance; human immunodeficiency virus; nucleocapsid protein; reverse transcriptase

Mesh:

Substances:

Year:  2020        PMID: 32747359      PMCID: PMC7508609          DOI: 10.1128/AAC.00958-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  79 in total

1.  Analysis of NCp7-dependent activation of HIV-1 cDNA integration and its conservation among retroviral nucleocapsid proteins.

Authors:  Leonora Poljak; Susan M Batson; Damien Ficheux; Bernard P Roques; Jean-Luc Darlix; Emmanuel Käs
Journal:  J Mol Biol       Date:  2003-06-06       Impact factor: 5.469

Review 2.  Advances in targeting nucleocapsid-nucleic acid interactions in HIV-1 therapy.

Authors:  Divita Garg; Bruce E Torbett
Journal:  Virus Res       Date:  2014-07-12       Impact factor: 3.303

3.  An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase.

Authors:  J Boretto; S Longhi; J M Navarro; B Selmi; J Sire; B Canard
Journal:  Anal Biochem       Date:  2001-05-01       Impact factor: 3.365

4.  Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance.

Authors:  A Mas; M Parera; C Briones; V Soriano; M A Martínez; E Domingo; L Menéndez-Arias
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

5.  Role of capsid sequence and immature nucleocapsid proteins p9 and p15 in Human Immunodeficiency Virus type 1 genomic RNA dimerization.

Authors:  Jafar Kafaie; Marjan Dolatshahi; Lara Ajamian; Rujun Song; Andrew J Mouland; Isabelle Rouiller; Michael Laughrea
Journal:  Virology       Date:  2008-12-13       Impact factor: 3.616

6.  Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.

Authors:  Sadahiro Tamiya; Sek Mardy; Mark F Kavlick; Kazuhisa Yoshimura; Hiroaki Mistuya
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Lay Myint; Masakazu Matsuda; Zene Matsuda; Yoshiyuki Yokomaku; Tomoko Chiba; Aiko Okano; Kaneo Yamada; Wataru Sugiura
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Rebekah Barr; Vinay K Pathak
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

9.  The relationship between HIV-1 genome RNA dimerization, virion maturation and infectivity.

Authors:  Masahisa Ohishi; Takashi Nakano; Sayuri Sakuragi; Tatsuo Shioda; Kouichi Sano; Jun-ichi Sakuragi
Journal:  Nucleic Acids Res       Date:  2010-12-23       Impact factor: 16.971

10.  Role of Gag in HIV Resistance to Protease Inhibitors.

Authors:  François Clavel; Fabrizio Mammano
Journal:  Viruses       Date:  2010-07-05       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.